Table 1 Demographic and baseline characteristics
Dabigatran 220 mg | Enoxaparin 40 mg | |
|---|---|---|
(n = 2,156) | (n = 2,157) | |
Number of treated patients | 2,156 | 2,157 |
Age, yr | 63 ± 11 | 63 ± 11 |
Females, n (%) | 1177 (54.6) | 1152 (53.4) |
Weight, kg | 79 ± 16 | 79 ± 16 |
Body mass indexa | 27.8 ± 4.7 | 27.6 ± 4.6 |
Previous VTE, n (%) | 65 (3.0) | 54 (2.5) |
Creatinine clearanceb, mL/min | 92 ± 31 | 93 ± 31 |
Racec, n (%) | ||
White | 2,051 (95.1) | 2,052 (95.1) |
Asian | 96 (4.4) | 88 (4.1) |
Black | 5 (0.2) | 12 (0.6) |
Other | 4 (0.2) | 5 (0.2) |
Geographical region, n (%) | ||
Western Europe | 1,282 (59.5) | 1,291 (59.9) |
Central Europe | 474 (22.0) | 470 (21.8) |
North America | 170 (7.9) | 168 (7.8) |
India | 91 (9.0) | 88 (4.1) |
Australia/New Zealand/South Africa | 139 (6.4) | 140 (6.5) |
Patients treated and operated, n (%) | 2,138 (99.2) | 2,134 (98.9) |
Anesthesiad, n (%) | ||
General alone | 525 (24.4) | 503 (22.3) |
Neuraxial alonee | 1,461 (67.8) | 1,486 (65.8) |
Combinationf | 149 (6.9) | 144 (6.4) |
Mean duration of surgery ± SD, min | 85.4 ± 30.2 | 85. ±30.4 |
Study treatment | ||
Mean time to first subcutaneous injectiong,h in relation to surgery, hr | –15.6 ± 20.7 | –15.2 ± 13.5 |
Mean time to first oral dose postsurgeryh, hr | 3.1 ± 2.6 | 3.2 ± 2.7g |
Median (range) duration of hospital stayi, d | 8.5 (3–51) | 8.5 (3–26) |
Median (range) treatment duration, d | 31.6 (1–89) | 31.7 (1–49) |